Business Trip

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss:How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risksLinks to topics in this episode:Atai life sciencesEtifoxineEsketamine & arketamineAtai’s S-1Psychedelic Pharmacist AssociationCalyx LawPsilocybin Alpha, Noetic Fundkratom, Salvinorin A, BNC210, mitragynineMike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter ThielPureTech Health, Akili Interactive LabsBT’s DemeRx EpisodeViridia Life Sciences, EmpathBio, Kures, Recognify Life SciencesRead the transcript here.Watch episode 9 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme musi

Today's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders.In this episode, we discuss:The science, experience and the safety behind Ibogaine’s “neurochemical reset”Navigating US drug regulatory system and securing Intellectual PropertyDeborah’s 30 journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approvedPartnership with ATAI Life SciencesLinks to topics discussed in this episode:Deborah MashDemeRxIbogaineNoribogaineTabernanthe IbogaBwiti ReligionHoward LotsofSerotonergicsLambarene - promoted as a mental and physical stimulantHabenulaAddiction Expert Gabor MatéRead the transcript here.Watch episode 8 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Medita by Crowander, Two Feet by Muted Circus, and Rain On Me by JBlanked.

Today's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business.In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness.In this episode, we discuss:Origin story of The Trip ReportThe complexities of clinical trialsDiversity, inclusion and reciprocity in psychedelic companiesLinks to topics discussed in this episode:The Trip ReportZach HaigneyOregon Measure 109 - 2020MAPSCOMPASS PathwaysUsonaPsilocybin AlphaBob Jesse - Council for Spiritual Practices5-HT2ASerotonin SyndromeNorthstar PledgeNagoya ProtocolFree, Prior, and Informed ConsentRead the transcript here.Watch episode 7 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Sun Inside by Ketsa and Better Days Ahead by Ketsa

Today's episode features Danny Motyka, founder of Psygen, a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin.Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis of psychedelic medicine. In this episode, we discuss:Behind the scenes of Psygen’s manufacturing processNatural vs Synthetic psychedelicsNavigating regulations for manufacturing Schedule 1 substancesLinks to topics discussed in this episode:GMPDr. Peter van der HeydenCOMP360Entourage EffectHealth CanadaNick Sand - Orange SunshineMDMA, LSD, 5-MeO-DMT, Ibogaine, PsilocybinEntheon BiomedicalMAPS2C-BRead the transcript here.Watch episode 6 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Crystals by Xylo-Ziko, Obscure Train by Revolution Void, Love Chances by Makaih Beats, and Kleptotonic Swing by Tri-Tachyon

Today's episode features Flor Bollini, founder of NANA, an online platform that guides patients on using psychedelic medicine for holistic healing.NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorporates ketamine, cannabis and CBD.Flor hopes these protocols will become best practices for patients, clinics, and the psychedelic medicine ecosystem.In this episode, we discuss:Why Flor transitioned from serving medicine to company founderDeveloping protocols where the FDA doesn’t regulateThe benefits of progressive dosingHer experiences with 5-MeO-DMT and Iboga. “The Everest of psychedelics” as she calls them.Links to topics discussed in this episode:UNESCO - United Nations Educational, Scientific and Cultural OrganizationIfa - Ancient Divination SystemAyurvedaJungian5-MeO-DMTLMS - Learning Management SystemREM Sleep - Rapid Eye Movement SleepSSRIs - Selective Serotonin Reuptake InhibitorsAyahuascaIbogaineBwiti religionSerotonin SyndromeRead the transcript here.Watch episode 5 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. DavisMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Blue Dot Sessions.

Today's episode features David Champion, CEO and co-founder of Maya, a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments.In this episode, we discuss:Removing the guesswork from developing psychedelic therapy protocolsFundraising tips for psychedelic company foundersThe role of data in surfacing safer and more effective treatmentsA big announcement from Matias and Greg!Links to topics discussed in this episode:Zendo Project - Subsidiary of MAPSJohns Hopkins - Center for Psychedelic and Consciousness ResearchMAPSCIISEMR & EHR - What's the difference?Read the transcript here.Watch episode 4 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. DavisMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Blue Dot Sessions.

Today's episode features Ryan Zurrer, founder of Vine Ventures, one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values.If you’re a founder, investor, or early hire at a psychedelic company, this episode is a must-listen!In this episode, we discuss:Which psychedelic business models are a good fit for venture capital?Why did Ryan start Vine Ventures?What traits of entrepreneurs does Ryan invest in?Which form of psychedelic medicine is better: natural or synthetic compounds? Links to topics discussed in this episode:PharmauascaOregon Initiative Measure 109ENTHEONPsyGenCalifornia SoberAtaiCompassGet in touch with Ryan Zurrer - TW: @rzurrer LI: Ryan ZurrerRead the transcript here.Watch episode 3 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. DavisFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Blue Dot Sessions and Chad Crouch

Today’s episode features Shelby Hartman and Madison Margolin from DoubleBlind, a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit company working on becoming a fully licensed certified B corporation.Links to topics discussed in this episode:What It’s Like to Have Sex on Different Kinds of Psychedelics How Oregon is Leading the Country in Drug Policy Reform Entheogen: Definition and History How Psychedelics are Reigniting JudaismMichael Pollan's book How to Change Your MindAyelet Waldman's book: A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My LifeMDMA Testing Kits from DanceSafeRead the transcript here.Watch episode 2 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. DavisFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Plasticity by Blue Dot SessionsIsEbOcbXwtgQS6Jzz1Eb

Today’s episode features Dylan Beynon from Mindbloom, a mental and wellbeing startup that is currently offering ketamine-assisted therapy to treat anxiety and depression. Mindbloom is opening clinics across the country and is using technology to lower the cost of treatment. Host Greg Kubin participates in a ketamine-assisted therapy session in the episode. And that ethereal track you hear during the ketamine session is called Happiness Frequency by Conscious Sounds 432hz.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Watch episode 1 on YouTube.Music: Sal by Xylo-Ziko, Ocean Waves by Siddhartha Corsus, Sun Heights by Muted Circus, Sita’s Song by Siddhartha Corsus, and Fair Detective by Muted Circus.Find us at businesstrip.fmFollow us on Instagram and Twitter!Find us at businesstrip.fm